Zacks Investment Research on MSN
NTRA debuts Zenith Genomics next-gen sequencing test for rare diseases
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to ...
Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...
Genomic sequencing has come a long way in a short time, and its potential to drive even faster innovations in precision medicine is enormous. To capitalize on that opportunity, however, health systems ...
Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people ...
Every year, millions of newborns undergo routine screening as a preventive strategy to detect inherited disorders before symptoms emerge. Newborn screening (NBS) programs have traditionally relied on ...
Patients with classic NF1 including the presence of cutaneous neurofibromas or Lisch nodules, as no genetic heterogeneity demonstrated so far associated with this phenotype. The NF1-only by NGS ...
Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results